ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has earned an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in […]

Related Keywords

Canada , United States , Robertw Baird , , Pharmaceuticals Inc , Group One Trading , Oric Pharmaceuticals Inc , Acadian Asset Management , Pharmaceuticals Daily , Citigroup , Pharmaceuticals Stock Performance , Nasdaq , Royal Bank , Ameritas Investment Partners Inc , Get Free Report , Investment Partners , Asset Management , Get Free , Oric Pharmaceuticals , Nasdaq Oric , Foric , Medical , Ratings , Consensus ,